-
41.
公开(公告)号:US20090197860A1
公开(公告)日:2009-08-06
申请号:US12274532
申请日:2008-11-20
申请人: Jianguo Ji , Tao Li , Kevin B. Sippy , Chih-Hung Lee , Murali Gopalakrishnan
发明人: Jianguo Ji , Tao Li , Kevin B. Sippy , Chih-Hung Lee , Murali Gopalakrishnan
IPC分类号: A61K31/4439 , C07D401/14 , C07D403/04 , A61K31/497 , A61P25/28 , A61P25/18
CPC分类号: C07D487/04
摘要: The invention relates biaryl substituted diazabicycloalkanes, and more particularly bicycloheteroaryl substituted fused diazabicycloalkane derivatives, compositions comprising such compounds, and methods of preventing or treating conditions and disorders using such compounds and compositions.
摘要翻译: 本发明涉及联芳基取代的二氮杂双环烷烃,更具体地是双环杂芳基取代的稠合二氮杂双环烷烃衍生物,包含这些化合物的组合物,以及使用这些化合物和组合物预防或治疗病症和病症的方法。
-
公开(公告)号:US09346810B2
公开(公告)日:2016-05-24
申请号:US13817802
申请日:2011-08-18
申请人: Wei-Guo Su , Wei Deng , Jinshui Li , Jianguo Ji
发明人: Wei-Guo Su , Wei Deng , Jinshui Li , Jianguo Ji
IPC分类号: C07D487/04
CPC分类号: A61K31/519 , A61K31/5377 , A61K45/06 , C07B2200/07 , C07D471/04 , C07D487/04
摘要: The present disclosure provides pyrrolopyrimidine compounds and methods of use therefor. For example, the disclosure provides certain pyrrolopyrimidine compounds capable of inhibiting JAK kinases. The disclosure further provides the pharmaceutical compositions containing these pyrrolopyrimidine compounds, and use of these pyrrolopyrimidine compounds in the treatment of disorders or diseases, such as inflammatory diseases and cancer.
摘要翻译: 本公开提供吡咯并嘧啶化合物及其使用方法。 例如,本公开提供了能够抑制JAK激酶的某些吡咯并嘧啶化合物。 本公开进一步提供含有这些吡咯并嘧啶化合物的药物组合物,以及这些吡咯并嘧啶化合物在治疗疾病或疾病如炎性疾病和癌症中的用途。
-
公开(公告)号:US20070275975A1
公开(公告)日:2007-11-29
申请号:US11749779
申请日:2007-05-17
申请人: Jianguo Ji , Tao Li , Ying Wang
发明人: Jianguo Ji , Tao Li , Ying Wang
IPC分类号: C07D453/00 , A61K31/4427 , A61K31/50 , C07D471/08 , A61P25/00 , C07D403/02
CPC分类号: C07D453/02
摘要: Compounds of formula (I) wherein A is N or N+—O−; n is 0, 1, or 2; Y is O, S, —NH—, and —N-alkyl-; Ar1 is both 6-membered aromatic rings; Ar2 is 5- or 6-membered aromatic rings with a —NR8R9 group, as defined herein. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.
摘要翻译: 式(I)的化合物,其中A是N或N +,-O - n为0,1或2; Y是O,S,-NH-和-N-烷基 - ; Ar 1是两个6元芳环; Ar 2是如本文所定义的具有-NR 8 R 9 R 9基团的5-或6-元芳环。 该化合物可用于治疗由α7nAChR配体预防或改善的病症或病症。 还公开了具有式(I)化合物的药物组合物和使用这些化合物和组合物的方法。
-
公开(公告)号:US20050159597A1
公开(公告)日:2005-07-21
申请号:US11015158
申请日:2004-12-17
申请人: Jianguo Ji , Tao Li , Ying Wang
发明人: Jianguo Ji , Tao Li , Ying Wang
IPC分类号: C07D453/02 , C07D487/04
CPC分类号: C07D453/02
摘要: Compounds of formula (I) wherein A is N or N+—O−; n is 0, 1, or 2; Y is O, S, —NH—, and —N-alkyl-; Ar1 is both 6-membered aromatic rings; Ar2 is 5- or 6-membered aromatic rings with a —NR8R9 group, as defined herein. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.
摘要翻译: 式(I)的化合物,其中A是N或N +,-O - n为0,1或2; Y是O,S,-NH-和-N-烷基 - ; Ar 1是两个6元芳环; Ar 2是如本文所定义的具有-NR 8 R 9 R 9基团的5-或6-元芳环。 该化合物可用于治疗由α7nAChR配体预防或改善的病症或病症。 还公开了具有式(I)化合物的药物组合物和使用这些化合物和组合物的方法。
-
公开(公告)号:US20050137398A1
公开(公告)日:2005-06-23
申请号:US10744484
申请日:2003-12-22
申请人: Jianguo Ji , Tao Li
发明人: Jianguo Ji , Tao Li
IPC分类号: A61K31/439 , C07D453/00 , C07D453/02
CPC分类号: C07D453/02
摘要: Compounds of formula (I) or a pharmaceutically acceptable salt, amide, or prodrug thereof, wherein: n is 0, 1, or 2; X1 is O, S, —N(R1)—, —N(Ar2)—, and N(R2)C(O)—; Ar1 is a six-membered aromatic ring; Ar2 is cyclohexyl or a mono- or bicyclic aromatic ring, as defined herein. The compounds are useful in treating conditions or disorders prevented by or ameliorated by nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.
摘要翻译: 式(I)化合物或其药学上可接受的盐,酰胺或前药,其中:n为0,1或2; X 1是O,S,-N(R 1) - , - N(Ar 2) - 和N(R 0) > 2)C(O) - ; Ar 1是6元芳环; Ar 2是如本文所定义的环己基或单环或双环芳环。 该化合物可用于治疗由nAChR配体预防或改善的病症或病症。 还公开了具有式(I)化合物的药物组合物和使用这些化合物和组合物的方法。
-
公开(公告)号:US20050137226A1
公开(公告)日:2005-06-23
申请号:US11015157
申请日:2004-12-17
申请人: Jianguo Ji , Tao Li
发明人: Jianguo Ji , Tao Li
IPC分类号: A61K31/4745 , C07D453/02
CPC分类号: C07D453/02
摘要: Compounds of formula: or pharmaceutically acceptable salts, esters, amides, or prodrugs thereof, wherein: A and G are each independently N or N+—O−; m and n are each independently 0, 1, or 2; X1 and X3 are each independently O, S, and —N(R1)—; X2 is O, S, —N(R1)—, —N(Ar2)—, and —N(R2)C(O)—; Ar1 is a six-membered aromatic ring; Ar2 is cyclohexyl or a mono- or bicyclic aromatic ring, and R13 is hydrogen, alkyl, or halogen, as defined herein. The compounds are useful in treating conditions or disorders prevented by or ameliorated by nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formulas (I) and (II) and methods for using such compounds and compositions.
摘要翻译: 式:或其药学上可接受的盐,酯,酰胺或前药的化合物,其中:A和G各自独立地为N或N +, - O - m和n各自独立地为0,1或2; X 1和X 3各自独立地为O,S和-N(R 1) - ; X 2是O,S,-N(R 1) - , - N(Ar 2) - 和-N(R' (O) - ; Ar 1是6元芳环; Ar 2是环己基或单环或双环芳环,R 13是如本文所定义的氢,烷基或卤素。 该化合物可用于治疗由nAChR配体预防或改善的病症或病症。 还公开了具有式(I)和(II)化合物的药物组合物以及使用这些化合物和组合物的方法。
-
公开(公告)号:US20050137184A1
公开(公告)日:2005-06-23
申请号:US10744208
申请日:2003-12-22
申请人: Jianguo Ji , Tao Li
发明人: Jianguo Ji , Tao Li
IPC分类号: A61K31/501 , A61K31/506 , A61K31/55 , C07D453/02
CPC分类号: A61K31/506 , A61K31/501 , A61K31/55 , C07D453/02
摘要: Compounds of formula (I) wherein n is 0, 1, or 2; X is O, S, —NH—, and —N-alkyl-; Ar1 is a 6-membered aromatic ring; and Ar2 is a fused bicycloheterocycle. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.
摘要翻译: 其中n为0,1或2的式(I)化合物; X是O,S,-NH-和-N-烷基 - ; Ar 1是6元芳环; 并且Ar 2是稠合的双环杂环。 该化合物可用于治疗由α7nAChR配体预防或改善的病症或病症。 还公开了具有式(I)化合物的药物组合物和使用这些化合物和组合物的方法。
-
公开(公告)号:US09434726B2
公开(公告)日:2016-09-06
申请号:US14124325
申请日:2012-06-07
申请人: Wei-Guo Su , Wei Deng , Jianguo Ji
发明人: Wei-Guo Su , Wei Deng , Jianguo Ji
IPC分类号: A61K31/4985 , C07D241/38 , C07D471/04 , C07D519/00
CPC分类号: A61K31/5377 , A61K31/4985 , A61K31/506 , A61K31/541 , A61K31/551 , A61K31/553 , C07D471/04 , C07D519/00
摘要: Provided are pyridopyrazine compounds of formula (I), pharmaceutical compositions thereof and methods of use therefore, wherein R1, R2, R3, R4 and m are as defined in the specification.
-
公开(公告)号:US20130210831A1
公开(公告)日:2013-08-15
申请号:US13817802
申请日:2011-08-18
申请人: Wei-Guo Su , Wei Deng , Jinshui Li , Jianguo Ji
发明人: Wei-Guo Su , Wei Deng , Jinshui Li , Jianguo Ji
IPC分类号: C07D487/04
CPC分类号: A61K31/519 , A61K31/5377 , A61K45/06 , C07B2200/07 , C07D471/04 , C07D487/04
摘要: The present disclosure provides pyrrolopyrimidine compounds and methods of use therefor. For example, the disclosure provides certain pyrrolopyrimidine compounds capable of inhibiting JAK kinases. The disclosure further provides the pharmaceutical compositions containing these pyrrolopyrimidine compounds, and use of these pyrrolopyrimidine compounds in the treatment of disorders or diseases, such as inflammatory diseases and cancer.
摘要翻译: 本公开提供吡咯并嘧啶化合物及其使用方法。 例如,本公开提供了能够抑制JAK激酶的某些吡咯并嘧啶化合物。 本公开进一步提供含有这些吡咯并嘧啶化合物的药物组合物,以及这些吡咯并嘧啶化合物在治疗疾病或疾病如炎性疾病和癌症中的用途。
-
50.
公开(公告)号:US20080045539A1
公开(公告)日:2008-02-21
申请号:US11748527
申请日:2007-05-15
申请人: Jianguo Ji , Tao Li , Christopher Lynch , Murali Gopalakrishnan
发明人: Jianguo Ji , Tao Li , Christopher Lynch , Murali Gopalakrishnan
IPC分类号: A61K31/46 , A61K31/497 , A61K31/501 , A61P25/18 , A61P25/28 , C07D221/22 , C07D401/12
CPC分类号: C07D451/08 , C07D451/14 , C07D519/00
摘要: The invention relates to fused bicycloheterocycle substituted azabicyclic alkane derivatives, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.
摘要翻译: 本发明涉及稠合的双环杂环取代的氮杂双环烷烃衍生物,包含这些化合物的组合物,以及使用这些化合物和组合物治疗病症和病症的方法。
-
-
-
-
-
-
-
-
-